Pds biotech announces updated survival data from nci-led phase 2 clinical trial of pds0101-based triple combination therapy in advanced hpv16-positive cancer patients which show 75% survival of ici naÏve patients at 36 months

Princeton, n.j., nov. 09, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary t cell activating platforms, today announced updated survival data from the phase 2 clinical trial investigating the triple combination of pds0101, pds0301 (il-12 antibody-drug conjugate) and an investigational immune checkpoint inhibitor (ici) in two groups of advanced cancer patients with various types of human papillomavirus (hpv) 16-positive cancers. the ici naÏve group had not responded to standard-of-care treatments but had not yet been treated with an ici. the ici resistant group included patients who had not responded to multiple prior treatments, including ici therapy. investigators at the national cancer institute (nci), part of the national institutes of health, have completed the primary endpoint analysis of the phase 2 trial.
PDSB Ratings Summary
PDSB Quant Ranking